



# Global Access Update BPAL/M

Sandeep Juneja

Senior Vice President, Market Access


TB Alliance

To date, **more than 70 countries** have procured pretomanid for use in these regimens to treat more than

**40,000 people**

with DR-TB

# Unprecedented pace of adoption of BPaL/M



**4-6X the  
treatments  
shipped**

**in 5 years since SRA approval  
than previous new drugs**


\* Projected based on orders for 2023 shipment

# Global Policy to Implement BPaL-Based Regimens

Almost all people with DR-TB could be treated with a six-month, all-oral, highly effective therapy under programmatic conditions.

Two BPaL-based regimens:

- **BPaLM:** Bedaquiline, pretomanid, linezolid, and moxifloxacin
- **BPaL:** Bedaquiline, pretomanid, linezolid



# Commercialization Partnerships

Collaborations with Viatris, Macleods Pharmaceuticals, Hongqi Pharmaceutical, Lupin Limited, and Remington Pharmaceuticals


- TB Alliance has signed five manufacturers to commercialize pretomanid as part of the **BPaL** regimen to advance the treatment of TB around the world



# Established Strong Value Proposition: BPaL/M is Highly Acceptable, Cost Saving & Cost Effective

- High acceptability of 88%. Highly cost effective and cost-saving
- Potential health systems savings of **USD 740 million** per year
- Potential savings of 40-75% for MDR-TB treatment and up to 90% for preXDR-TB treatment
- DALYs averted up to 56%


Regions with varied TB burden and TB/HIV co-infection & Global




GE, ID, KG, NG, PH, ZA, Global



# Traditionally, the road to access is long...




# Compared to how we've worked to maximize collaboration and bridge the gap between research and access







# Ensuring Affordability at the Start



# And Improving Quickly



\*Limited countries

Pa Volume Guarantee with MedAccess & Viatrix in sync with WHO guidelines (Dec-2022)

# Early Country Engagement; Implementation Projects in Key Regions



- In 7 early adopters: catalyze accelerated implementation under **operational research** conditions initially
- **Scale-up** following updated WHO guidelines
- **Capacity building** in several program aspects
- **1<sup>st</sup> OR** commenced **within 5 months** of WHO guidelines
- **1<sup>st</sup> prog. roll-out within 1 month** of new WHO guidelines
  
- **South Africa, Pakistan, Peru, Tajikistan:** implementation planning, pilot projects, or financing for initial implementation: based on each country's expressed needs. Also implementing speedily
- Scientific engagement with all high burden countries and many more



Co-funded by:




Visit [www.lifttb.org](http://www.lifttb.org)



Details on LIFT-TB updates at the Union

# Global Access Partners in Research and Implementation



# Community Collaborations for Inclusive Approach

Partnering with civil society to fast-track introduction and scale at the country-level



India



Philippines



Vietnam



Indonesia



Together with the Stop TB Partnership



**FAST TRACK  
THE CURE**



**Six-month  
drug-resistant  
TB cures  
for all**

**#6MonthsMax**

**Find out more about  
Fast Track the Cure**

## What we have learned and next steps

---

- Access planning begins early in R&D
- Crucial for PDPs to take charge of access along with R&D, and being proactive and deliberate
- PDPs lack commercial motive hence uniquely placed to engage and collaborate with countries, communities, global health stakeholders such as WHO, Global Fund, Stop-TB
- PDPs are well placed to build local capacity – a broader goal than developing & introducing products
- Countries with strong program leadership bring innovations to their patients faster

### **Immediate next priorities (underway)**

- Expand work to further countries in support of political declaration of UN HLM about treatment access
- Foster experience sharing from countries where we have worked to others
- Planning for improved formulations
- Planning for pipeline candidates such as TBAJ-876

# Toward a TB Free World:

## TB Alliance Stakeholders Association Annual Meeting

Tuesday, 14 November 2023 | 5:00 - 6:30pm CET

Paris Marriott Champs Elysees Hotel

70 Avenue des Champs-Élysées, 75008, Paris, France

### Panel Moderated by:



**Oxana Rucsineanu**  
SMIT,  
Moldova



**Priyanka Aiyer**  
Global Fund  
Advocates Network

### Panelists:



**Lada Bulakh**  
Member of Parliament,  
Committee on epidemic  
security, HIV/ AIDS, and  
socially dangerous diseases,  
Ukraine



**Abdul Ghafoor**  
MDR-TB Advisor to  
National TB Program,  
Ministry of Health,  
Pakistan




**Siti Nadia Tarmizi**  
Director of  
Communications Bureau,  
Ministry of Health,  
Indonesia



**Fernanda Dockhorn**  
National TB Program,  
Ministry of Health,  
Brazil



**Norbert Ndjeka**  
Chief Director, TB Control and  
Management,  
National Department of Health,  
South Africa



**Scan here to enter  
your questions**



# Toward a TB Free World:

## TB Alliance Stakeholders Association Annual Meeting

# Thank you for joining!

Please join us for a reception | 6:30 - 8:30pm CET